Matches in Wikidata for { <http://www.wikidata.org/entity/Q58100570> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q58100570 description "artículu científicu espublizáu n'ochobre de 2018" @default.
- Q58100570 description "im Oktober 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58100570 description "scientific article published on 29 October 2018" @default.
- Q58100570 description "wetenschappelijk artikel" @default.
- Q58100570 description "наукова стаття, опублікована в жовтні 2018" @default.
- Q58100570 name "Response to: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand" @default.
- Q58100570 name "Response to: 'Lupus Low Disease Activity State" @default.
- Q58100570 type Item @default.
- Q58100570 label "Response to: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand" @default.
- Q58100570 label "Response to: 'Lupus Low Disease Activity State" @default.
- Q58100570 prefLabel "Response to: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand" @default.
- Q58100570 prefLabel "Response to: 'Lupus Low Disease Activity State" @default.
- Q58100570 P1433 Q58100570-0597F0FD-94A0-4CC5-A127-4244DEB344FE @default.
- Q58100570 P1476 Q58100570-DB79B5B9-525C-4B46-9B89-F05BA91C6828 @default.
- Q58100570 P304 Q58100570-410DEEEE-BA6E-4468-B027-45EDE1160005 @default.
- Q58100570 P31 Q58100570-EEA222CF-AE65-4FBF-B9AE-E26DB4822065 @default.
- Q58100570 P356 Q58100570-28D22502-0134-4401-95E2-6C7A9FB9543C @default.
- Q58100570 P407 Q58100570-FF6D7BDC-06D2-47F1-8674-ED622FA293E6 @default.
- Q58100570 P433 Q58100570-0BBAF89C-49E7-4224-A215-2237EE668772 @default.
- Q58100570 P478 Q58100570-B38021EC-948A-4DA5-8F4B-366CF7E4B162 @default.
- Q58100570 P50 Q58100570-7375D628-769B-4C81-A6EF-9F47C7105310 @default.
- Q58100570 P577 Q58100570-C1E8ECEB-72FB-42A0-804D-F99D14AC6C3D @default.
- Q58100570 P698 Q58100570-D40F17A8-D0E2-4036-A993-082887066D6E @default.
- Q58100570 P921 Q58100570-52610F31-EB5C-46EB-979A-1DC8EA5E82DF @default.
- Q58100570 P356 ANNRHEUMDIS-2018-214468 @default.
- Q58100570 P698 30373882 @default.
- Q58100570 P1433 Q4767876 @default.
- Q58100570 P1476 "Comment on: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al" @default.
- Q58100570 P304 "e121" @default.
- Q58100570 P31 Q13442814 @default.
- Q58100570 P356 "10.1136/ANNRHEUMDIS-2018-214468" @default.
- Q58100570 P407 Q1860 @default.
- Q58100570 P433 "11" @default.
- Q58100570 P478 "78" @default.
- Q58100570 P50 Q42326409 @default.
- Q58100570 P577 "2018-10-29T00:00:00Z" @default.
- Q58100570 P698 "30373882" @default.
- Q58100570 P921 Q1485 @default.